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A B S T R A C T
Aims: Vitamin D is a fat-soluble vitamin classically known for its role in calcium absorption and bone
health. Growing evidence indicates that vitamin D deﬁciencymay be associated with inﬂammation, insulin
resistance, and obesity. However, prior studies examining the association of vitamin D with metabolic
risk factors had relatively low representation of individuals of black race, limiting their ability to char-
acterize associations of vitamin D and parameters of metabolic health in black vs. white individuals.
Methods: We examined associations of 25-hydroxyvitamin D (25(OH)D) concentrations with markers
of inﬂammation (interleukin [IL]-6, IL-10, high sensitivity C-reactive protein [hsCRP]), insulin sensitiv-
ity (adiponectin, resistin, HOMA-IR), and obesity (body mass index [BMI], waist circumference) in 1042
participants from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a large
national cohort of black and white adults 45 years or older.
Results: In unadjusted analyses, lower 25(OH)D concentrations were associated with higher IL-6 and hsCRP
concentrations; lower adiponectin concentrations; higher HOMA-IR; and higher BMI and waist circum-
ference (P < 0.05 for all). After adjustment for sociodemographic, clinical, lifestyle, and laboratory variables,
lower 25(OH) D concentrations remained associated with lower adiponectin concentrations, higher IL–6
concentrations, higher HOMA-IR, and higher BMI and waist circumference (P < 0.05 for all). The magni-
tude of these associations did not differ by race (Pinteraction > 0.1).
Conclusions: Lower 25(OH)D concentrations are associated with disturbances in metabolic health in both
blacks and whites. Whether correcting vitamin D deﬁciency could offer a beneﬁcial therapy for disease
prevention requires further study.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Vitamin D is a fat-soluble vitamin and hormone essential for
calcium absorption and bone health. Vitamin D status is most com-
monly determined by serum concentrations of 25-hydroxyvitamin
D (25(OH)D), the storage form of vitamin D. Epidemiologic data have
established that a large portion of the population has vitamin D de-
ﬁciency, generally deﬁned as 25(OH)D concentrations <20 ng/ml.
Though vitamin D is classically known for its function in skeletal
health, studies have shown that low 25(OH)D concentrations are
associated with obesity, insulin resistance, and inﬂammation [1–6],
suggesting that vitamin D has pleiotropic actions which impact nu-
merous physiologic systems involved in metabolic health.
Prior studies that examined the associations of 25(OH)D with
markers ofmetabolic health have been limited by relatively low rep-
resentation from black individuals. This is important in that both
vitamin D deﬁciency and established metabolic risk factors such as
visceral adiposity, hypertension and inﬂammation aremore common
in black individuals than in white individuals. Further, prior studies
have shown racial differences in the association of 25(OH)D with
markers of insulin resistance [7,8], suggesting that the association of
25(OH)D with other metabolic risk factors may differ by race. Few
studieshaveexaminedassociationsof 25(OH)Dwithmarkersof insulin
resistance, obesity and inﬂammation in a large sample of black and
white adults. Accordingly, we examined the association of 25(OH)D
with markers of inﬂammation, insulin resistance, and obesity in
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participants of the Reasons for Geographic and Racial Differences in
Stroke (REGARDS) study, a prospective cohort of community-dwelling
black and white adults living throughout the United States (US).
Methods
Study participants
The REGARDS study is a population-based investigation of stroke
incidence in black and white US adults ≥45 years of age. Details of
the study design have been reviewed elsewhere [9]. Brieﬂy, par-
ticipants were recruited from the 48 contiguous US states and the
District of Columbia. The study was designed to provide approxi-
mately equal representation of men and women, and oversampled
black individuals and persons living in the “stroke belt/buckle” of
the US (Georgia, Alabama, North Carolina, South Carolina, Tennes-
see, Arkansas, Mississippi, and Louisiana). Trained interviewers
conducted computer-assisted telephone interviews to obtain in-
formation including participants’ socio-demographics, cardiovascular
risk factors, tobacco usage, physical activity, and use of medica-
tions. Following this interview, an in-home study visit was conducted
that included an electrocardiograph (ECG) recording, inventory of
medications and collection of blood and urine samples.
Overall, 30,239 black and white adults were enrolled between
January 2003 and October 2007 (42% black, 55% women). For this
study, we used a subset of participants with measured plasma
25(OH)D concentrations (n = 1042) who were randomly selected
from the REGARDS Study population using a stratiﬁed sampling pro-
cedure to ensure suﬃcient representation of participants from high
risk categories (e.g., black individuals and older participants), as pre-
viously described [10]. Brieﬂy, all participants with at least one
follow-up contact (n = 29,653) were categorized into 20 strata based
on age (45–54, 55–64, 65–74, 75–84, ≥85 years), race (black orwhite),
and sex (male or female). In each stratum, participants were ran-
domly selected to fulﬁll the desired distribution: 50% black, 50%
white, 50% female, 50% male, 20% age 45–54, 20% age 55–64, 25%
age 65–74, 25% age 75–84, and 10% age ≥85. Each individual was
assigned a weight that was calculated as the inverse of their sam-
pling fraction, with the sample weight representing the number of
individuals in the full REGARDS cohort represented by that one
person in the subcohort. All analyses were performed using this
weight, which effectivelymakes the results reﬂect the original sample
(as indicated by the weighted N).
The REGARDS study protocol was approved by the Institutional
Review Boards governing research in human subjects at the partici-
pating centers and all participants providedwritten informed consent.
Data collection
Plasma 25(OH)D was measured in baseline samples using a
commercially-available ELISA (Immunodetection Systems, Foun-
tain Hills, AZ). The assay range was 5–150 ng/ml. Intra-assay
coeﬃcients of variation (CVs) were 8.82–12.49%. Interleukin (IL) 6
was measured by ultra-sensitive ELISA (Quantikine HS Human IL-6
Immunoassay; R&D Systems, Minneapolis, MN), with an inter-
assay CV range of 6.8–7.3%. IL-10 was measured using the Milliplex
MAP Human Cardiovascular Disease (CVD) Panel 3 (Millipore Cor-
poration; Billerica, MA) run as a single-plex assay with an inter-
assay CV range of 8.3–12.1%. High sensitivity C-reactive protein
(hsCRP) was measured by particle enhanced immunonephelometry
using the BNII nephelometer (N High Sensitivity CRP; Dade Behring,
Deerﬁeld, IL) with inter-assay CVs of 2.1–5.7% [11]. Serum glucose
and insulin were measured using the Ortho Vitros 950 IRC Clinical
Analyzer (Johnson & Johnson Clinical Diagnostics, Raritan, NJ) and
Roche Elecsys 2010 System (Roche Diagnostics, Indianapolis, IN),
respectively. Insulin resistance was assessed using the homeosta-
sis model assessment [HOMA-IR = insulin [mg/dL] × glucose [mg/
dL]/405] [12]. Fasting insulin was only obtained in participants
without a history of diabetes, so calculations of HOMA-IR were only
available for those without diabetes (n = 810). Resistin and
adiponectin were measured using Human Serum Adipokine Panel
A LINCOplex Kit (Linco Research, Inc.; St. Charles, MO). Inter-assay
CVs ranges from 8.0–13.2% and 6.1–10.4%, respectively.
Age, race, sex, annual family income, educational attainment, and
tobacco use history were determined by self-report. Bodymass index
(BMI)was calculated asweight in kilogramsdivided byheight inmeters
squared measured during the in-home visit. Waist circumference (in
centimeters) was measured during the in-home visit using a tape
measure positionedmidway between the lowest rib and the iliac crest
with the participant standing. Systolic and diastolic blood pressure BP
were deﬁned as the average of twomeasurements taken by a trained
technician using a standard protocol, after the participant was seated
for 5 minutes. Physical activity was assessed through a single ques-
tion: “How many times per week do you engage in intense physical
activity, enough to work up a sweat,” with response options of: none,
1–3 times/week or >4 times/week. History of coronary heart disease
(CHD) was deﬁned as having any of the following: evidence of myo-
cardial infarction on the baseline ECG, self-report of a prior history of
a cardiac procedure (coronary artery bypass surgery or percutaneous
angioplasty), or self-reported history of myocardial infarction. History
of stroke was ascertained by self-report. Diabetes was deﬁned as self-
reporteduseof insulin or oral hypoglycemic agents, fastingbloodglucose
concentration of 126mg/dL or higher, or a non-fasting blood glucose
concentration of 200mg/dL or higher. Dyslipidemia was deﬁned as a
serum total cholesterol concentration ≥240mg/dL, low-density lipo-
protein concentration ≥160 mg/dL or high-density lipoprotein
concentration <40mg/dL, or a self-reported prior diagnosis of high cho-
lesterol or current use of cholesterol-loweringmedications. Phosphorus
and calcium concentrations were measured using standard assays.
Serum intact parathyroid hormone concentrations (PTH) were mea-
sured using a commercially available ELISA (Roche Elecsys 2010, Roche
Diagnostics, Indianapolis, IN)with intra- and inter-assay CVs range from
2 to 4% and 3 to 6%, respectively.
Serum creatinine was calibrated to an international isotope di-
lution mass spectroscopic (IDMS)-traceable standard, measured by
colorimetric reﬂectance spectrophotometry. Estimated glomeru-
lar ﬁltration rate (eGFR) was calculated using the CKD-EPI equation
[13]. Albumin and creatinine were measured in a random spot urine
specimen by nephelometry (BN ProSpec Nephelometer, Dade
Behring, Marburg, Germany) and Modular-P chemistry analyzer
(Roche/Hitachi, Indianapolis, IN), respectively. Spot urine albumin-
to-creatinine ratio (UACR) was calculated in mg/g. Prevalent CKD
was deﬁned as an eGFR <60 ml/min/1.73 m2 or a UACR ≥30 mg/g.
Statistical analyses
Standard descriptive statistics were used to examine demo-
graphic, clinical and laboratory characteristics of the participants
in the overall sample across clinically-relevant categories of 25(OH)D
(<20 ng/ml, 20–29 ng/ml, ≥30 ng/ml). To account for the stratiﬁed
sampling design of the subcohort, all analyses were weighted by
the inverse probability of the random cohort sampling fraction. Linear
regressionmodels were used to examine the association of 25(OH)D
as the primary independent variable with markers of inﬂamma-
tion (IL-6, IL-10, hsCRP), insulin resistance (resistin, adiponectin,
HOMA-IR) and BMI and waist circumference as the dependent vari-
ables of interest. The initial models were adjusted for age, sex, race,
and region of residence. The second model was adjusted for pa-
rameters in Model 1 plus indices of socioeconomic status (annual
household income, educational achievement), history of diabetes
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(except for models examining HOMA-IR), CHD, stroke, and lifestyle
habits (cigarette smoking, physical activity) and seasonof blooddraw.
The third model further adjusted for laboratory parameters (eGFR,
UACR, calcium, phosphorus, and intact PTH). Because IL-6, IL-10,
resistin, adiponectin, hsCRP and UACR were not normally distrib-
uted, we log-transformed these variables for all analyses. We
examined effect modiﬁcation by race status by testing the signiﬁ-
cance (P < 0.1) ofmultiplicative interaction terms in themodels.When
signiﬁcant interactionwas detected, we analyzed stratiﬁedmodels.
A two-tailed P value <0.05 was considered statistically signiﬁcant
for all analyses other than the tests for interaction, inwhich a P value
< 0.1 was considered statistically signiﬁcant. All analyses were con-
ducted using SAS software version 9.4 (SAS Institute, Cary, NC).
Results
Baseline characteristics of study participants according to cat-
egories of 25(OH)D concentrations are depicted in Table 1. Lower
25(OH)D concentrations were associated with female sex, black race,
higher systolic and diastolic blood pressure, lower educational
achievement and income, a greater prevalence of current smoking,
diabetes, and dyslipidemia, and higher eGFR and intact PTH
concentrations.
Table 2 presents markers of inﬂammation, insulin resistance and
obesity by 25(OH)D categories. Lower 25(OH)D concentrations were
associated with higher BMI, waist circumference, IL-6, and hsCRP
concentrations and higher HOMA-IR, and lower concentrations of
adiponectin. There were no statistically signiﬁcant associations of
25(OH)D with IL-10 or resistin. Race did not modify the associa-
tions of 25(OH)D with any of these markers (Pinteraction > 0.1 for all,
Supplementary Table S1).
Table 3 depicts multivariable adjusted associations of 25(OH)D
with markers of inﬂammation, insulin resistance and obesity.
Plasma 25(OH)D concentrations were inversely associated with
log-transformed IL-6 concentrations after adjustment for sociode-
mographic variables, geographic region of residence, and clinical,
lifestyle, and laboratory factors (0.14 log-unit lower IL-6 per 10 ng/
ml higher 25(OH)D, P < 0.001). In contrast, the inverse association
of 25(OH)D with hsCRP in the unadjusted analysis presented in
Table 2 was attenuated and no longer statistically signiﬁcant after
adjustment for age, sex, race and geographic region of residence
(Model 1, Table 3).
With respect to markers of insulin resistance, plasma 25(OH)D
concentrations were directly associated with adiponectin concen-
trations (0.09 log-unit higher adiponectin per 10 ng/ml higher
25(OH)D, P < 0.001) and inversely associated with HOMA-IR (0.13
log-unit lower HOMA-IR per 10 ng/ml higher in 25(OH)D, P < 0.001)
in models adjusted for sociodemographic, clinical, and laboratory
variables. There was no association of 25(OH)D with resistin in any
multivariable-adjusted model. Race did not modify the associa-
tions of 25(OH)Dwith any of the markers of inﬂammation or insulin
resistance (Pinteraction > 0.1 for all).
Higher 25(OH)D concentrations were associated with lower BMI
(−0.72 kg per 10 ng/ml higher 25(OH)D, P = 0.002) and waist cir-
cumference (−2.3 cm per 10 ng/ml higher 25(OH)D, P < 0.001) in fully
adjusted models. Race did not modify the associations of 25(OH)D
with either of the measures of obesity (Pinteraction > 0.1 for both).
Discussion
In this study, we found that lower 25(OH)D concentrations were
associated with higher IL-6 and HOMA-IR, lower adiponectin, and
Table 1
Baseline characteristics according to 25-hydroxyvitamin D (25(OH)D) concentrations in the cohort random sample (analyses weighted to the full cohort). Results presented
as means (95% conﬁdence interval) or frequencies
25(OH)D
<20 ng/ml
25(OH)D
20–29 ng/ml
25(OH)D
≥30 ng/ml
Weighted N 8737 10,580 8709
Age, years (95% CI) 64.5 (63.6,65.4) 65.3 (64.5,66.2) 65.1 (64.1,66.1)†
Male (%) 36 46 51†
Black (%) 75 32 18†
Region of residencea
Non-stroke belt (%) 47 49 45†
Stroke belt (%) 53 51 55
Systolic blood pressure, mm Hg (95% CI) 130.2 (128.0,132.4) 126.8 (125.1,128.6) 124.7 † (122.7,126.7)
Diastolic blood pressure, mm Hg (95% CI) 78.2 (77.0,79.3) 76.1 (75.2,77.2) 74.6 (73.3,75.9) †
Less than high school education (%) 18 11 6†
Annual income <$20,000/year (%) 24 11 12†
Physical activity (%)
None 44 32 25†
1 to 3 times per week 31 42 33
4 or more times per week 24 25 41
Co-morbidities
Current smoking (%) 19 11 12†
Diabetes (%) 33 20 10†
Coronary heart disease (%) 13 16 20†
Atrial ﬁbrillation (%) 8 9 9
Dyslipidemia (%) 63 56 60
eGFR, ml/min/1.73 m2 (95%CI) 88.8 (86.2,91.4) 85.7 (83.7,87.7) 83.2 (81.0,85.5)†
eGFR <60 ml/min/1.73 m2 (%) 10 7 8†
Albumin to creatinine ratio, mg/g (95% CI) 49.4 (28.7,70.2) 27.9 (15.6,40.3) 22.5 (13.8,31.3)†
Urinary ACR >30 mg/g (%) 18 11 10†
Parathyroid hormone, pg/ml (95% CI) 59.0 (53.9,64.2) 42.7 (40.9,44.6) 37.5 (35.4,39.5)†
Calcium, mg/dL (95% CI) 9.2 (9.1,9.3) 9.1 (8.9,9.2) 9.2 (9.1,9.3)
Phosphorus, mg/dL (95% CI) 3.5 (3.4,3.5) 3.5 (3.4,3.5) 3.5 (3.4,3.6)
eGFR, estimated glomerular ﬁltration rate; ACR, albumin to creatinine ratio.
a Stroke belt includes persons living in US stroke belt (North Carolina, South Carolina, Georgia, Tennessee, Mississippi, Alabama, Louisiana, and Arkansas) or buckle (coastal
plain regions of Georgia, North Carolina and South Carolina) states.
† P-value < 0.05.
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higher waist circumference and BMI independently of other risk
factors in community dwelling adults. Furthermore, the magnitude
and strength of these associations did not differ signiﬁcantly by race.
These data support the ﬁndings of prior studies that vitamin D is in-
dependently associated withmarkers of metabolic health and unlike
prior studies, suggest that these relationships do not differ by race.
The associations between vitamin D and insulin resistance, in-
ﬂammation, and obesity have been previously reported. Consistent
with the ﬁndings of the current study, prior studies found an inverse
association of serum 25(OH)D concentrations with insulin resis-
tance [1,5,6] and pro-inﬂammatory markers such as IL-6 and CRP
[14,15]. Similarly, multiple prior studies have shown an inverse as-
sociation of BMI with 25(OH)D, which is attributed to the fat-
soluble nature of vitamin D and sequestration into adipose tissue
[2,16]. However, these previous studies included relatively low
numbers of black individuals, precluding deﬁnitive examination of
racedifferences. This is important in that several prior studies showed
racial heterogeneity in the association of vitamin D with markers
of metabolic health. In the National Health and Nutrition Exami-
nation Surveys from 1988 to 1994 (NHANES III) and from 2001 to
2006, lower 25(OH)D concentrations were shown to be associated
with greater prevalence of insulin resistance and diabetes in non-
Hispanicwhite andMexican-American participants, but not in non-
Hispanic black participants [7,8]. Conversely, our results showed that
the association between circulating 25(OH)D concentrations, insulin
resistance, inﬂammation and obesity does not differ by race, as other
studies have suggested [17]. Further, to our knowledge, this is the
ﬁrst study to examine the association of 25(OH)D with adipokines
such as resistin andadiponectin andmarkers of inﬂammationbeyond
hsCRP such as IL-6 and IL-10 in a population-based sample with an
adequate representation of black individuals. Thus the current study
adds to the literature by indicating that 25(OH)D concentrationsmay
bean importantmarker ofmetabolic health inbothblacks andwhites.
Although low25(OH)D concentrations have been linked to insulin
resistance, inﬂammation, andobesity in several observational studies
including the current one, the effect of vitamin D supplementation
remains uncertain. Whereas animal studies have found vitamin D
supplementation during deﬁciency can improve insulin resistance,
these ﬁndings have not been reliably reproduced in human sub-
jects [18–21]. Similarly, trials of vitamin D supplementation have
not been shown to affect inﬂammation inhumanparticipants [14,22].
Though vitamin D supplementation has not aided in weight loss, it
has been found that obese subjects experience a decreased dose re-
sponse to vitamin D supplements [2]. There are several important
differences between animal and human trials. Most human trials
have included relatively healthy participants who are not always
vitamin D deﬁcient. Furthermore, the dose of supplementation and
goal 25(OH)D concentration varied greatly between studies. Most
studies lasted approximately 3months, often duringwintermonths,
and only a fewwere 6months to a year ormore in duration. In order
to appreciate any role vitamin Dmay have in insulin resistance, in-
ﬂammation, andobesity, it is possible that vitaminDsupplementation
Table 2
Clinical and laboratory parameters by category of 25-hydroxyvitamin D. Values given as mean (95% conﬁdence interval) or median [interquartile range]
Parameter Overall Category 1
(<20 ng/ml)
Category 2
(20–30 ng/ml)
Category 3
(>30 ng/ml)
P
25(OH)D ng/ml 25.3 (24.1,26.5) 14.7 (14.4,15.1) 24.7 (24.4,25.1) 38.0 (36.9,39.0) <0.001
Obesity measures
Body mass index (kg/m2) 29.2 (28.8,29.6) 31.1 (30.2,31.9) 28.9 (28.4,29.6) 27.4 (26.7,28.1) <0.001
Waist circumference (cm) 95.7 (94.7,96.7) 99.9 (97.9,101.9) 95.0 (93.4,96.6) 91.8 (90.1,93.5) <0.001
Inﬂammatory markers
Interleukin-6 (pg/ml) 2.7 [1.8,4.2] 3.4 [3.0,3.7] 2.7 [2.5,2.9] 2.1 [1.9,2.3] <0.001
Interleukin-10 (pg/ml) 9.0 [6.0,13.2] 9.0 [8.1,9.9] 8.9 [8.0,9.8] 9.1 [8.3,9.8] 0.17
hsCRP (mg/L) 2.1 [0.9,4.9] 2.8 [2.3,3.3] 2.0 [1.7,2.3] 1.7 [1.3,2.0] <0.001
Insulin resistance markers
HOMA-IR 2.2 [1.3,3.5] 2.7 [2.3,3.0] 2.3 [2.1,2.5] 1.8 [1.5,2.1] <0.001
Resistin (pg/ml) 24.1 [18.3,30.8] 24.7 [23.1,26.4] 23.4 [21.9,24.9] 24.6 [23.6,25.9] 0.33
Adiponectin (ng/ml) 10.8 [6.0,18.8] 9.3 [8.3,10.3] 11.8 [10.4,13.1] 12.7 [10.4,15.1] <0.001
Abbreviations: hsCRP, high-sensitivity C-reactive protein; HOMA-IR, homeostatic model assessment of insulin resistance.
Table 3
Associations between 25-hydroxyvitamin D and markers of inﬂammation (interleukin-6, high-sensitivity C-reactive protein, and interleukin-10), insulin resistance (resistin,
adiponectin, homeostasis model assessment-insulin resistance), and obesity measures (body mass index, waist circumference)
Inﬂammatory markers Insulin resistance markers Obesity measures
IL-6 hsCRP IL-10 Resistin Adiponectin HOMA-IR BMI Waist circumference
Model 1
β −0.14 −0.06 −0.02 −0.02 0.09 −0.13 −1.1 −3.2
P-value <0.001 0.18 0.63 0.31 0.003 <0.001 <0.001 <0.001
Model 2
β −0.11 −0.02 −0.02 −0.02 0.10 −0.12 −0.87 −2.6
P-value <0.001 0.67 0.47 0.33 0.004 <0.001 <0.001 <0.001
Model 3
β −0.11 −0.01 −0.03 −0.01 0.13 −0.13 −0.72 −2.3
P-value <0.001 0.93 0.53 0.44 <0.001 <0.001 0.002 <0.001
Abbreviations: IL-6, interleukin-6; hsCRP, high-sensitivity C-reactive protein; IL-10, interleukin-10; HOMA-IR, homeostasis model assessment of insulin resistance; BMI,
body mass index.
β-coeﬃcients for IL-6, hsCRP, IL-10, resistin, and adiponectin are presented as log-unit change in each parameter per 10 ng/ml change in 25(OH)D.
Model 1 is adjusted for age, sex, race, region of residence.
Model 2 is adjusted for variables in Model 1 plus indices of socioeconomic status, history of diabetes (except for HOMA-IR models), coronary heart disease, stroke, lifestyle
habits (tobacco usage, physical activity) and season of blood draw.
Model 3 is adjusted for variables in Model 2 plus eGFR, log albumin-to-creatinine ratio, phosphorus, calcium and intact parathyroid hormone.
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should focus on vitaminD deﬁcient individualswith chronic disease
conditions particularly amenable to vitamin D replacement, such
as diabetes [23]. Interestingly, adjusting for physical activity did not
affect themagnitude or strength of the associations of 25(OH)Dwith
insulin resistance, inﬂammation and obesity, suggesting that the as-
sociations described herein do notmerely reﬂect healthier lifestyle
but may instead represent direct biological links between lower
25(OH)D and poor metabolic health.
This study had several strengths worth mentioning. The large,
bi-racial REGARDS population allowed us to examine the associa-
tion of 25(OH)D with indices of metabolic health in blacks and
whites. Additionally, the participants were geographically diverse,
and therefore regions with different rates of sun-exposure were all
represented. However, there are also important weaknesses to con-
sider. First, this observational and cross-sectional study cannot
answer the ongoing questions of causality, directionality, or time
course of the associations found. Additionally, 25(OH)Dwas the only
vitamin D metabolite measured. Vitamin D binding protein, 24,25
(OH)2D and 1,25(OH)2D were not measured, which may have pro-
vided important insight into other factors that may impact
associations of 25(OH)D with insulin sensitivity and/or differ-
ences in these associations by race [24].
In conclusion, these ﬁndings bolster the link between vitamin
D deﬁciency and metabolic health and supports the notion that
vitamin D deﬁciency and poor metabolic health are relevant to both
black and white individuals. So far, vitamin D supplementation has
not yet been shown to substantially improve metabolic health pa-
rameters such as insulin sensitivity and inﬂammation in human trials,
despite experimental data showing direct causal links between
vitamin D deﬁciency and poor metabolic health. However, as the
prevalence of metabolic syndrome in the general population con-
tinues to rise, this area of research remains relevant, particularly
in populations such as black individuals who have a higher overall
prevalence of vitamin D deﬁciency and are at increased risk of poor
metabolic health [25]. Further randomized controlled trials in clearly
deﬁcient individuals with chronic disease conditions are warranted.
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